METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2. (2021)

Peer-Reviewed Study · Hamidi-Alamdari D; Hafizi-Lotfabadi S; Bagheri-Moghaddam A; Safari H; Mozdourian M; Javidarabshahi Z; Peivandi-Yazdi A; Ali-Zeraati A; Sedaghat A; Poursadegh F; Barazandeh-Ahmadabadi F; Agheli-Rad M; Tavousi SM; Vojouhi S; Amini S; Amini M; Majid-Hosseini S; Tavanaee-Sani A; Ghiabi A; Nabavi-Mahalli S; Morovatdar N; Rajabi O; Koliakos G · 2021

Hamidi-Alamdari D et al., 2021: Iranian randomised trial of oral methylene blue plus standard care in 80 hospitalised severe COVID-19 patients – a real trial behind methylene blue in the same pandemic setting where hydroxychloroquine's authorisation was withdrawn.

In an academic medical center, 80 hospitalized patients with severe COVID-19 were randomly assigned to receive either oral MB along with standard of care (SOC) (MB group, n = 40) or SOC only (SOC group, n=40).

Hamidi-Alamdari D et al., 2021: Iranian randomised trial of oral methylene blue plus standard care in 80 hospitalised severe COVID-19 patients – a real trial behind methylene blue in the same pandemic setting where hydroxychloroquine's authorisation was withdrawn. C13 Hamidi-Alamdari 2021. Study type: randomised, controlled, open-label phase 2 trial, N=80 (40 MB, 40 standard of care). Country: Iran (Mashhad University of Medical Sciences). Dose/route: oral reduced methylene blue; the mg dose is not in the abstract text captured. Funder/conflicts: not in the record. Comparator: standard of care. PARTLY: one small open-label single-country trial does not establish a general parallel between the two drugs; recorded because the comparison is the claim under test. Also filed as MTL-051, MTQ-076 (claims C13, C4, C8). Study type: randomized trial.